Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1997-01-24
1998-12-01
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
A61K 3119
Patent
active
058439960
ABSTRACT:
The intravenous use of magnesium gluconate to substantially block free radical surge in the treatment of ischemia/reperfusion (I/R) injury due to oxidative stress is disclosed.
REFERENCES:
patent: 5108365 (1992-04-01), Woods, Jr. et al.
patent: 5370989 (1994-12-01), Stern et al.
Mak et al., Enhanced NO production durintg MG deficiency and its role in mediating red blood cell glutathione loss, 1996, pp. C385-C390, the American Physiological Society.
Jackimczyk, Jr. et al., Alternatives to Thrombolytic Therapy, Dec. 1995, 73-76, Emergency Medicine.
Ronald Smetana, M.D. BPh, Cardiovascular Medicine--Acute Myocardial Infarction: The Importance of Magnesium as a Pharmacological Agent, Vienna, Austria, Jun. 16, 1995, Supplement to American Heart Jounal, vol. 132, No. 2, Part 2 (Aug., 1996).
Glogar, et al, Management of acute myocardial infaraction: Evaluating the past, practicing in the present, elaborating the future. 1996, 465-470.
Seelig, et al., Is there a place for magnesium in the treatment of acute myocardial infarction? Aug. 1996, 471-477, American Heart Journal.
Steurer, M.D., et al., Acute myocardial infarction, reperfusion injury, and intravenous magnesium therapy: Basic concepts and clinical implications, American Heart Journal, vol. 132, No. 2, part 2, 478-482 (1996).
Schechter, M.D., et al., The rationale of magnesium as alternative therapy for patients with acute myocardial infarction without thrombolytic therapy, Aug., 1996, 483-486, American Heart Journal.
Elliott M. Antman, M.D., Magnesium in acute myocardial infarction: Overview of available evidence, Aug., 1996, 487-502, American Heart Journal.
Mak et al., Antioxidant Activity of Calcium Channel Blocking Drugs, Methods in Enzymology, vol. 234, 620-630 (1994).
Wu et al., Beijing Yike Daxue Xuebao (1992), 24(2), 112-14 (Abstract).
LandOfFree
Intravenous magnesium gluconate for treatment of conditions caus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Intravenous magnesium gluconate for treatment of conditions caus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intravenous magnesium gluconate for treatment of conditions caus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2396095